BA
INSY

Boston Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Boston Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-11,680
Closed -$332K – 776
2015
Q3 		$332K Sell
11,680
-790
-6% -$29.1K 0.01% 644
2015
Q2 		$448K Buy
+12,470
New +$388K 0.02% 505

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Boston Advisors's INSY Position: Q4 2015 in Review

Boston Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q4 2015, closing a stake of 11,680 shares — an estimated $332K sold.

Boston Advisors first reported a position in INSY in Q2 2015 and held it in 2 quarters. The position peaked at $448K in Q2 2015. 154 funds tracked by Wall St. Rank hold INSY as of Q4 2015.

  • Boston Advisors reported no remaining Insys Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Boston Advisors sold 11,680 Insys Therapeutics, Inc. shares in Q4 2015, an estimated $332K.
  • Boston Advisors first reported a position in Insys Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Boston Advisors's Insys Therapeutics, Inc. position peaked at $448K in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2015.

Based on Boston Advisors's 13F filing for Q4 2015, filed 20 Jan 2016.